浙江昂利康制药股份有限公司2025年第三次临时股东会决议公告

Group 1 - The company held its third extraordinary general meeting of shareholders on December 16, 2025, to discuss significant matters, including the issuance of A-shares to specific targets [3][4][6] - The meeting was attended by 404 shareholders and representatives, representing 50.0819% of the total voting shares [5] - The company ensured that the voting process included separate counting for minority investors to enhance their participation [2] Group 2 - The proposal for the issuance of A-shares was approved with 99.6421% of the votes in favor, indicating strong support from shareholders [6] - The company plans to issue A-shares to specific targets, with the total number of shares and pricing principles also approved during the meeting [7][11][12] - The total expected amount for daily related transactions for 2025 was increased to RMB 16.55 million, reflecting adjustments based on operational needs [28][29] Group 3 - The company confirmed that the adjustments to related transactions do not exceed 0.5% of the latest audited net assets, thus falling within the general manager's decision-making authority [30] - The company maintains that the related transactions are conducted at market prices and are essential for normal business operations, ensuring no adverse impact on financial conditions [33]

ALK-浙江昂利康制药股份有限公司2025年第三次临时股东会决议公告 - Reportify